Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

BACKGROUND: Regorafenib is an orally available, small-molecule multikinase inhibitor with international marketing authorizations for use in colorectal cancer and gastrointestinal stromal tumors. In clinical trials, regorafenib showed a consistent and predictable adverse-event profile, with hand–foot...

Full description

Saved in:
Bibliographic Details
Published in:Ann Oncol
Main Authors: McLellan, B., Ciardiello, F., Lacouture, M. E., Segaert, S., Van Cutsem, E.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2015
Subjects:
Reviews
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4576906/
https://ncbi.nlm.nih.gov/pubmed/26034039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv244
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items